Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Utility of Amyloid Beta and Tau Positron Emission Tomography Scans for Identifying Early-Stage Neurodegenerative Changes in Former Professional Football Players and Healthy Controls: Results from the Brain Health Initiative.

Journal of neurotrauma·2026
Same author

Bench-to-Bedside Evaluation of Sulforaphane/BroccoMax on Fatty Acid Synthesis in Prostate Cancer.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Bench-to-Bedside Evaluation of Sulforaphane/BroccoMax® on Fatty Acid Synthesis in Prostate Cancer.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Angiographic Predictors of Outcomes After Balloon Test Occlusion.

Stroke (Hoboken, N.J.)·2026
Same author

Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment.

JCO precision oncology·2026

Related Experiment Video

Updated: Mar 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case

Nghi C Nguyen1, Muhammad Shah1, Leonard J Appleman2

  • 1Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.

International Journal of Molecular Imaging
|October 25, 2016
PubMed
Summary

Radium-223 dichloride (Xofigo) is an alpha-particle therapy for metastatic prostate cancer, showing survival benefits. Ongoing trials explore its use in earlier disease stages and combination therapies for various cancers.

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.7K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background:

  • Radium-223 dichloride (Xofigo) is the first FDA-approved alpha-particle emitter for treating metastatic castrate-resistant prostate cancer (CRPC).
  • Post hoc analyses of the ALSYMPCA trial confirm its safety, therapeutic efficacy, and positive clinical outcomes in CRPC patients.
  • Current research investigates Radium-223 in earlier disease stages and in combination with other treatments.

Approach:

  • This article provides a comprehensive review of Radium-223 dichloride.
  • It covers the physics and radiobiology of alpha-particle emission.
  • A literature update and case presentations are included to aid clinical practice.

Key Points:

  • Radium-223 dichloride offers benefits in overall survival and delays symptomatic skeletal events in metastatic CRPC.
  • Ongoing clinical trials are expanding its application to earlier disease stages and combination therapies.
  • Investigational uses include breast, thyroid, and renal cancers metastatic to bone.

Conclusions:

  • Radium-223 dichloride is an established therapy for metastatic CRPC with a favorable safety profile.
  • Further research and clinical trials are exploring its expanded use in oncology.
  • This review aims to enhance the understanding and clinical application of Radium-223 data.